five

Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory Metastatic Colorectal Cancer

收藏
NIAID Data Ecosystem2026-03-12 收录
下载链接:
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2696054
下载链接
链接失效反馈
官方服务:
资源简介:
Interventions: Arm A:tislelizumab combined with cetuximab and irinotecan Primary outcome(s): Overall response rate (ORR) Study Design: Single arm
创建时间:
2021-01-15
二维码
社区交流群
二维码
科研交流群
商业服务